Current issues in Hereditary Angioedema (HAE) - Ipopi
Current issues in Hereditary Angioedema (HAE) - Ipopi Current issues in Hereditary Angioedema (HAE) - Ipopi
Recent initiatives • World consensus document published July 2010 – Earlier treatment of acute attacks – New treatments • C1 inhibitor, icatibant, ecallantide – FFP (plasma) obsolete – Lower doses of danazol/stanozolol – Self administration available for everyone who wants it – http://www.aacijournal.com/content/6/1/22 or 24 • Trials of self-administration of icatibant • Subcutaneous C1 inhibitor • Higher doses of C1 inhibitor • rC1 inhibitor for Europe-early 2011 • Ecallantide for Europe- 2011 • USA patient-led database • Icatibant outcome survey
- Page 1 and 2: Current issues in Hereditary Angioe
- Page 3 and 4: What is HAE (Hereditary • HAE 1 o
- Page 5 and 6: C1 inhibitor controls inflammation
- Page 7 and 8: What have we learnt about the new
- Page 9 and 10: • Berinert (C1 inhibitor) trials
- Page 11 and 12: Treatment of C1 inhibitor deficienc
- Page 13 and 14: Icatibant (Firazyr) • Recurrent a
- Page 15 and 16: Living with hereditary angioedema:
- Page 17 and 18: L’s story: 25 year old with HAE
- Page 19 and 20: L’s story •15 th March 2010- 2
- Page 21 and 22: Treatment of C1 inhibitor deficienc
- Page 23 and 24: Self administration C1 ınhıbıtor
- Page 25 and 26: C1 inhibitor controls local Healthy
- Page 27: Rational use of steroids….
- Page 30 and 31: Mr B 15 years • Unwilling to trai
- Page 32 and 33: Mrs B 42 years • Danazol 100 mg a
- Page 34 and 35: Need to control acute attacks
- Page 36 and 37: What does everyone want • Patient
Recent <strong>in</strong>itiatives<br />
• World consensus document published July 2010<br />
– Earlier treatment of acute attacks<br />
– New treatments<br />
• C1 <strong>in</strong>hibitor, icatibant, ecallantide<br />
– FFP (plasma) obsolete<br />
– Lower doses of danazol/stanozolol<br />
– Self adm<strong>in</strong>istration available for everyone who wants it<br />
– http://www.aacijournal.com/content/6/1/22 or 24<br />
• Trials of self-adm<strong>in</strong>istration of icatibant<br />
• Subcutaneous C1 <strong>in</strong>hibitor<br />
• Higher doses of C1 <strong>in</strong>hibitor<br />
• rC1 <strong>in</strong>hibitor for Europe-early 2011<br />
• Ecallantide for Europe- 2011<br />
• USA patient-led database<br />
• Icatibant outcome survey
Change language